Ionis Pharmaceuticals (IONS) Q2 2024 earnings summary

Executive summary

• Achieved significant milestones in 2024, including multiple positive Phase 3 readouts, successful launches of WAINUA in the U.S. and QALSODY in the EU, and strong pipeline advancement across several therapeutic areas.

• WAINUA launch for hereditary ATTR polyneuropathy is progressing well, with approvals in Canada, anticipated EU decision in 2024, and strong uptake among new and switching patients.

• Olezarsen NDA for FCS accepted for FDA Priority Review with a PDUFA date of December 19, 2024; EU filing planned and launch preparations underway.

• Donidalorsen showed positive Phase 3 data for HAE, with launch planned for 2025 and commercialization rights in Asia-Pacific granted to Otsuka.

• ION582 for Angelman syndrome showed positive early results, with Phase 3 study planned for H1 2025.

Financial highlights

• Q2 2024 revenue was $225.3 million, up 20% year-over-year; H1 2024 revenue reached $345 million.

• Commercial revenue for Q2 2024 was $72 million, including $3.8–$4 million from WAINUA royalties and $56.7–$57 million from SPINRAZA royalties.

• Operating expenses for Q2 2024 were $291–$291.3 million, up from $278.6–$279 million in Q2 2023, mainly due to increased SG&A for new launches.

• Net loss for Q2 2024 was $66–$66.3 million, improved from $85–$85.3 million in Q2 2023; basic and diluted net loss per share was $0.45.

• Cash, cash equivalents, and short-term investments totaled $2.1 billion as of June 30, 2024.

Outlook and guidance

• On track to achieve 2024 guidance: revenue over $575 million, projected year-end cash of $1.7 billion, and clear path to positive cash flow.

• Commercial revenue expected to increase as WAINUA and QALSODY launches ramp and SPINRAZA royalties rise.

• R&D revenue expected to be lower in the second half due to milestone timing; modest expense growth anticipated.

• Multiple product launches and regulatory milestones anticipated through 2025, including independent U.S. launches for olezarsen and donidalorsen.

• Opportunity for a $30 million milestone payment from AstraZeneca if WAINUA is approved in the EU.